| INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy, accounting for 3% of all cases of gastrointestinal cancer.
1,2 ICC makes up about 5-10% of all cholangiocarcinomas and originates from bile ducts within the liver parenchyma. 2, 3 Histologically, the majority of advanced ICC tumors are adenocarcinoma, which are typically treated with a combination of cytotoxic nucleoside analogs and platins. 4, 5 When feasible, complete surgical resection of ICC remains the only possible option for cure with an estimated median survival ranging from 27 to 36 months. [6] [7] [8] [9] However, only a minority of patients with ICC present with surgically resectable A minor hepatectomy was defined as a hepatic resection of less than 3 Couinaud segments. Suspected lymph node metastases on preoperative scans were considered suspicious preoperative lymph nodes, while only pathologically proven metastases were considered proven metastases. Patients with suspected lymph nodes preoperatively, and confirmed lymph node metastases during pathological examination of the resection specimen, were considered to have lymph node disease preoperatively and postoperatively, respectively.
Patients with suspected lymph node disease preoperatively, but no evidence in the resection specimen, were considered to only have lymph node metastases preoperatively.
The American Joint Committee on Cancer (AJCC) 7th edition staging was used to stratify patients by extent of disease. 13 Margin status was categorized as R0 for a negative margin, R1 when the margin was microscopically positive and R2 when the margin was macroscopically positive. Only patients undergoing a curative intent surgery for histologically confirmed ICC were included in the final study population; patients who did not undergo resection were excluded. Patients who underwent transplantation were also excluded. The respective institutional review boards of each participating institution approved this study. On final pathology, the majority of patients had an R0 resection (n = 42, 73.7%). Lymph node metastasis was noted in 24.2% of patients (n = 15). Twelve patients (25.5%) who had lymph node metastases on the preoperative work-up did not have lymph node metastasis on final pathology.
| Statistical analysis

| Receipt of preoperative chemotherapy
The majority of patients who received pCT (n = 50) were treated within the past 10 years, however the rate of pCT remained stable over the study period (P = 0.632). Several clinicopathologic features were associated with receipt of pCT (Table 2) 
| Perioperative morbidity
Overall morbidity among all patients who underwent resection for ICC was 40.2% (n = 420) with a higher incidence of complications occurring among patients who received pCT (pCT: n = 36, 59.0% vs no pCT: n = 384, 39.0%; P = 0.002); major morbidity, however, did not differ between the two groups (P = 0.568) ( Table 3 ). Median length of stay (pCT: 9 days, IQR 6,15 vs no pCT: 12 days, IQR 7,17; P = 0.080) and perioperative mortality within 90 days of surgery (pCT: n = 1, 2.2% vs no pCT: n = 35, 3.9%; P = 0.569) also did not differ between the two groups. Readmission within 30 days from surgery, however, was more common among patients who received pCT (pCT: n = 8, 15.7% vs no pCT: n = 39, 4.8%; P = 0.001). Post-operatively, patients in the pCT group more often received adjuvant chemotherapy (50.8% vs 29.0%, P = 0.001).
3.4 | Impact of preoperative chemotherapy on overall and disease-free survival 
| DISCUSSION
Preoperative therapy is used in several intra-abdominal cancers to reduce local and micrometastatic tumor burden prior to complete surgical resection. Some benefits of pCT include the potential to down-size tumors to increase resectability rates among patients who are initially deemed unresectable. Furthermore, pCT can potentially improve completeness of surgical resection, as well as help select patients with a better tumor biology, thereby improving OS and DFS.
In the current study, we examined a large, multi-institutional international cohort of patients receiving pCT for ICC. As the use of pCT among patients with ICC has not been well-studied, this represents to our knowledge the largest study to date analyzing the impact of pCT among patients undergoing curative-intent resection for ICC. We noted that patients with more advanced disease were more likely to receive pCT. Of note, the use of pCT did result in higher overall but not major perioperative morbidity. Furthermore, in the propensity score-matched cohort, there was a suggestion that pCT improved OS and DFS, however these differences did not reach statistical significance perhaps due to a small sample size.
The use of pCT has not been examined among patients with ICC in any prospective clinical trial to date. Likely due to the overall low incidence of ICC, patients with ICC are often grouped in clinical trials with other patients with biliary tract cancers. As such, the benefit of pCT in patients with ICC is ill-defined and not commonly utilized. 2, [14] [15] [16] In fact, in the current multi-institutional international cohort, the overall utilization of pCT was only 5.9%. This is likely due to the fact that analyses from available studies have been unable to show a reproducible benefit with the use of pCT among patients with ICC. 2, 16 Among patients with pancreatic adenocarcinoma, however, pCT has been used in patients with locally advanced tumors to define the tumor biology. 17 In the current cohort, patients with more advanced disease were more likely to receive pCT − suggesting that physicians were using pCT, in part, to help define the natural history of the disease. Specifically, patients with more preoperative suspected or biopsy-proven lymph node metastasis, as well as those patients with worse pathological tumor features more commonly received pCT. Unfortunately, as the current cohort only included patients undergoing curative-intent hepatic resection for ICC, we were unable to determine the rate of resectability among patients with locally advanced disease. Of note, on final pathology, the use of pCT did not improve complete R0 resection rates. This is likely multifactorial, but largely be due to the selection of pCT use for patients with tumors characterized by worse pathological features.
Patients who received pCT had increased minor, but not major perioperative morbidity or mortality rates versus patients who did not receive pCT. This is similar to previously published data regarding the safety of pCT among patients undergoing resection for intraabdominal cancer. 18, 19 Despite having more advanced disease and undergoing larger hepatic resections, patients who received pCT had equivalent peri-operative mortality and LOS. While long-term OS and DFS were comparable among patients who did and did not receive pCT, propensity score-matched analysis suggested a possible benefit of pCT regarding both OS and DFS-although the association did not Overall survival stratified by preoperative chemotherapy (P = 0.900) In a different study, Tamandl et al reported on 10 patients with ICC who were treated with pCT and noted no survival benefit. 21 While the current study was one of the largest series to examine ICC patients to receive pCT (n = 62), we similarly failed to find an effect of pCT on long-term outcomes. As noted, however, the sample size was still relatively small and therefore future prospective studies are needed.
In this study, we included 18 patients who received preoperative intra-arterial chemotherapy, as opposed to the 44 patients who received systemic chemotherapy. Intra-arterial therapy consists of the delivery of high doses of chemotherapy directly to the arterial circulation. 9 This results in high first pass extraction rates and minimizes systemic toxicity, as tumors derive most of their supply from the arterial circulation. 9, 22 The effects of intra-arterial therapy have been described in two clinical trials and a retrospective analysis, which showed promising results in patients with liver-confined disease in a palliative setting. 9, 23, 24 In our cohort, the lower percentage of patients with preoperatively confirmed lymph node metastases in the intra-arterial chemotherapy group (26.7% vs 44.7%), suggests that intra-arterial therapy was most often used preoperatively in patients with suspected borderline resectable disease, as opposed to patients with suspected micrometastatic disease. Although our finding is in line with current literature on patients with irresectable disease, future studies are needed to confirm the validity of this approach prior to a curative resection.
Results of the current study should be interpreted in the context of several limitations. As noted, the number of patients treated with pCT was small as the overall utilization was only 5.9%. Therefore, the lack of statistical significance was likely related to a type II error.
Additionally, inherent to all retrospective analyses, there may have been a selection bias regarding the diagnosis and treatment of patients. The inclusion of multiple centers also did not allow for the standardization of operative approach or protocols related to the use of pCT or adjuvant chemotherapy. The multi-center nature of the study adds to the generalizability of the study, allowing the finding to be applied across a wide range of patient populations.
| CONCLUSIONS
In conclusion, pCT utilization among patients with ICC is higher among patients with more advanced disease. In this large, multi-institutional cohort, the use of pCT did not impact short-term peri-operative outcomes such as morbidity or LOS. While OS and DFS following resection were not significantly different across treatment groups, propensity matching suggested possible improved outcomes in patients treated with pCT. Further prospective trials are needed, however, to better define the role of pCT and to identify the subset of patients who might yield the most clinical benefit from the use of pCT.
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